Literature DB >> 15482833

Localisation of osteogenic and osteoclastic cells in porous beta-tricalcium phosphate particles used for human maxillary sinus floor elevation.

Ilara R Zerbo1, Antonius L J J Bronckers, Gert de Lange, Elisabeth H Burger.   

Abstract

We and others have shown earlier that porous beta-tricalcium phosphate (TCP) (Cerasorb) can be used in patients to augment the maxillary sinus floor prior to placement of oral dental implants. To better understand the transformation of TCP particles into bone tissue, we analyse here the appearance of cells with osteogenic or osteoclastic potential in relation to these particles. In biopsies taken at 6 months after sinus floor augmentation we observed bone growth into the TCP particles but also replacement by soft connective tissue. To identify possible osteoprogenitor cells in this tissue, histological sections were immunostained with an antibody to Runx2/Cbfa1, an essential and early transcription factor for osteoblast differentiation. The osteogenic potential of cells was further confirmed by immunostaining for bone sialoprotein (BSP) and osteopontin (OPN). Other sections were stained for Tartrate Resistant Acid Phosphatase (TRAP) activity to identify cells with osteoclastic capacity. Runx2/Cbfa1 positive connective tissue cells were found in abundance throughout and around the TCP particles, even at a distance of several millimetres from the maxillary bone surface. About 95% of the cells found within TCP particles stained positive for Runx2/Cbfa1. Fewer cells stained positive for BSP and OPN, suggesting more mature osteoblastic properties. Mono- and binucleate TRAP-positive cells, but no multinucleate TRAP-positive osteoclasts, were found in the soft tissue infiltrating the TCP and at the surface of the TCP particles. Both the Runx2/Cbfa1 positive and the TRAP-positive cells decreased apically with increasing vertical distance from the maxillary bone surface. This data suggests that the TCP particles attract osteoprogenitor cells that migrate into the interconnecting micropores of the bone substitute material by 6 months. The lack of large multinucleate TRAP positive cells suggests that resorption of the TCP material by osteoclasts plays only a minor role in its replacement by bone. Chemical dissolution, possibly favoured by a high cell metabolism in the particles, seems the predominant cause of TCP degradation. The abundance of Runx2/Cbfa1 positive cells would indicate that with a greater time of healing there will be further bone deposition into these particles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15482833     DOI: 10.1016/j.biomaterials.2004.05.003

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  27 in total

Review 1.  Matrices and scaffolds for drug delivery in dental, oral and craniofacial tissue engineering.

Authors:  Eduardo K Moioli; Paul A Clark; Xuejun Xin; Shan Lal; Jeremy J Mao
Journal:  Adv Drug Deliv Rev       Date:  2007-04-18       Impact factor: 15.470

2.  The homing of bone marrow MSCs to non-osseous sites for ectopic bone formation induced by osteoinductive calcium phosphate.

Authors:  Guodong Song; Pamela Habibovic; Chongyun Bao; Jing Hu; Clemens A van Blitterswijk; Huipin Yuan; Wenchuan Chen; Hockin H K Xu
Journal:  Biomaterials       Date:  2013-01-05       Impact factor: 12.479

Review 3.  Biocomposites and hybrid biomaterials based on calcium orthophosphates.

Authors:  Sergey V Dorozhkin
Journal:  Biomatter       Date:  2011 Jul-Sep

4.  The combination of mesenchymal stem cells and a bone scaffold in the treatment of vertebral body defects.

Authors:  Václav Vaněček; Karel Klíma; Aleš Kohout; René Foltán; Ondřej Jiroušek; Jiří Šedý; Jan Štulík; Eva Syková; Pavla Jendelová
Journal:  Eur Spine J       Date:  2013-09-07       Impact factor: 3.134

5.  Comparison of the long-term effects on rabbit bone defects between Tetrabone and β-tricalcium phosphate granules implantation.

Authors:  Sungjin Choi; I-Li Liu; Kenichi Yamamoto; Muneki Honnami; Shinsuke Ohba; Ryosuke Echigo; Takamasa Sakai; Kazuyo Igawa; Shigeki Suzuki; Ryouhei Nishimura; Ung-Il Chung; Nobuo Sasaki; Manabu Mochizuki
Journal:  J Artif Organs       Date:  2014-08-13       Impact factor: 1.731

6.  Beta-tricalcium phosphate/type I collagen cones with or without a barrier membrane in human extraction socket healing: clinical, histologic, histomorphometric, and immunohistochemical evaluation.

Authors:  Bozidar M B Brkovic; Hari S Prasad; Michael D Rohrer; George Konandreas; George Agrogiannis; Dragana Antunovic; George K B Sándor
Journal:  Clin Oral Investig       Date:  2011-03-03       Impact factor: 3.573

7.  Maxillary sinus floor augmentation on humans: Packing simulations and 8 months histomorphometric comparative study of anorganic bone matrix and β-tricalcium phosphate particles as grafting materials.

Authors:  A Martinez; J Franco; E Saiz; F Guitian
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2010-06-15       Impact factor: 7.328

8.  Guided bone regeneration in standardized calvarial defects using beta-tricalcium phosphate and collagen membrane: a real-time in vivo micro-computed tomographic experiment in rats.

Authors:  Sundar Ramalingam; Abdulaziz Al-Rasheed; Aws ArRejaie; Nasser Nooh; Mohammed Al-Kindi; Khalid Al-Hezaimi
Journal:  Odontology       Date:  2015-07-09       Impact factor: 2.634

9.  Short (15 minutes) bone morphogenetic protein-2 treatment stimulates osteogenic differentiation of human adipose stem cells seeded on calcium phosphate scaffolds in vitro.

Authors:  Janice R Overman; Elisabet Farré-Guasch; Marco N Helder; Christiaan M ten Bruggenkate; Engelbert A J M Schulten; Jenneke Klein-Nulend
Journal:  Tissue Eng Part A       Date:  2012-11-16       Impact factor: 3.845

10.  Biodegradable β-tricalcium phosphate cement with anti-washout property based on chelate-setting mechanism of inositol phosphate.

Authors:  Toshiisa Konishi; Shuhei Takahashi; Zhi Zhuang; Kohei Nagata; Minori Mizumoto; Michiyo Honda; Yasuhiro Takeuchi; Hitomi Matsunari; Hiroshi Nagashima; Mamoru Aizawa
Journal:  J Mater Sci Mater Med       Date:  2013-03-08       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.